Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
OctreoPharm Sciences announced that the FDA has granted Orphan Drug designation to OPS202, an investigational radiotracer, based on a next generation antagonistic somatostatin analog for the management of neuroendocrine tumors.
RELATED: Oncology Resource Center
OPS202 is currently being studied in Phase 1/2 clinical trials. It has the potential to improve imaging of neuroendocrine tumor patients, which may lead to a change in disease management of those patients. Since the peptide can deliver up to 5 times more dose to the tumor compared to currently used second-generation agonists like DOTA-TATE, DOTA-TOC or DOTA-NOC, OctreoPharm Sciences is developing the same peptide as an therapeutic drug (OPS201) following a Theranostic approach.
For more information visit OctreoPharm.com.
